# TMC125-C223: TMC125 in HIV-1 Infected Subjects

> **NCT00081978** · PHASE2 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 211 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** TMC125

## Key facts

- **NCT ID:** NCT00081978
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2010-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00081978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00081978, "TMC125-C223: TMC125 in HIV-1 Infected Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00081978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*